genprowebdirectory
GEN Edge
News
Insights
Trends for 2021
Trends for 2020
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Current Issue
Past Issues
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Get GEN Edge
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
GEN Edge
Gene Therapy
AI Gets Gene Therapy Over the Immunity Hump
Coronavirus
Immunai Expands from Observational to Functional Genomics
Monoclonal Antibodies
RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision
Bioprocessing
OliX Advancing in Nucleic Acid Therapeutics
CAR T-Cells
‘Manufacturing-First Approach’ Pays Off for Cell Therapy Developer Artiva
News
Genome Editing
Now on Base, Rutgers Team Reveals New Genome Editing Approach
News
Phage Therapy Successful in Mice, but Resistance Looms
OMICs
Cellular Health Maintenance System Degradation May Lead to Advanced Huntington’s
News
Atopic Dermatitis Potentially Treated by Strain of Bacteria
Diabetes
Glucagon Receptor Blockade Promotes Recovery of Functional β-Cell Mass in Diabetic…
Insights
All
Trends for 2021
Trends for 2020
Bioprocessing
COVID-19 Increasing Risk of Cyberattacks for Digital Biopharma
Bioprocessing
Case Study: How to Accelerate COVID-19 Vaccine Development
Bioprocessing
Flexibility is Key to Advances in Biomanufacturing
Bioprocessing
People Are Key to the Digital Evolution of Biopharma
A-Lists
January 2021 Vol. 41 No. 1
Seven Biopharma Trends to Watch in 2021
A-Lists
Top 15 Best-Selling Drugs Launched in 2020
A-Lists
Top 50 NIH-Funded Institutions of 2020
July 2020 Vol. 40 No. 7
Top 10 Earners among Women Biopharma Executives
June 2020 Vol. 40 No. 6
In Praise of Lesser-Sung Life Sciences Clusters
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Bioprocessing
COVID-19 Increasing Risk of Cyberattacks for Digital Biopharma
Bioprocessing
Case Study: How to Accelerate COVID-19 Vaccine Development
Bioprocessing
Flexibility is Key to Advances in Biomanufacturing
Genome Editing
Now on Base, Rutgers Team Reveals New Genome Editing Approach
Magazine
Current Issue
Past Issues
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Home
Antibodies
Monoclonal Antibodies
Page 32
Monoclonal Antibodies
Random
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Monoclonal Antibodies
Viral Hemorrhagic Fever Treatment Developed
Monoclonal Antibodies
Novartis’ Canakinumab Shows Benefits in Two Phase III Gouty Arthritis Studies
Monoclonal Antibodies
Opsona Awarded €5.9M EC Grant for Clinical Trials of mAB in Solid Organ Transplantation
Monoclonal Antibodies
Emergent BioSolutions and TLV Set Up Influenza-Focused JV
Monoclonal Antibodies
Biogen Idec and Genentech Tweak Anti-CD20 Alliance to Prevent Future Squabbles
Monoclonal Antibodies
Genzyme’s mAb for Multiple Sclerosis Succeeds in Second Phase III Trial
Monoclonal Antibodies
Genentech and Pfizer Join the Antibody-Drug Conjugate Bandwagon
Monoclonal Antibodies
Morphotek Taps Synageva in Cancer and Infectious Disease Deal
Monoclonal Antibodies
FDA Clears Roche/Chugai’s mAb for Rheumatoid Arthritis
Monoclonal Antibodies
Effimune, In Cell Art Launch Cancer Immunotherapy Collaboration
Monoclonal Antibodies
Lilly Poised to Submit BLA for Migraine mAb Following Three Successful...
Monoclonal Antibodies
mAb Therapeutics for Alzheimer Disease Unlikely to Be Fully Successful, According...
Monoclonal Antibodies
BI Taps MacroGenics in Multibillion-Dollar Deal for Antibody Development
Monoclonal Antibodies
Lilly Ends Phase III Rheumatoid Arthritis Program
Monoclonal Antibodies
XOMA Licenses TGFb Immuno-Oncology Program to Novartis for Up to $517M+
1
...
31
32
33
Page 32 of 33
Scroll Up
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
/* The alert message box */ .alert { padding: 20px; background-color: #ff9800; /* Red */ color: white; margin-bottom: 15px; } /* The close button */ .closebtn { margin-left: 15px; color: white; font-weight: bold; float: right; font-size: 22px; line-height: 20px; cursor: pointer; transition: 0.3s; } /* When moving the mouse over the close button */ .closebtn:hover { color: black; } .td_module_flex_2 .entry-title { font-size: 17px; line-height: 20px; }
![Genentech will tap Spirogen’s technology and Pfizer will use Seattle Genetics’.[Sebastian Kaulitzki-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesJan2011Jan6_2011_8300503_AntibodiesBlood_BIandMacroGenicsAntibodyDeal1727281211-324x160.jpg "Genentech and Pfizer Join the Antibody-Drug Conjugate Bandwagon")
![Firm will get $60 million over the first three years to use its DART platform.[Sebastian Kaulitzki-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesOct2010Oct26_2010_8300503_AntibodiesBlood_BIandMacroGenicsAntibodyDeal1151433122-324x160.jpg "BI Taps MacroGenics in Multibillion-Dollar Deal for Antibody Development")
![Antibody therapy reduced risk of new attacks by up to 68% compared with steroids.[© falkjohann - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/May25_2011_2997038_PeopleWalkingSticksDog_NovartisPhIIIGoutyArthritis2482335117-265x198.jpg "Novartis’ Canakinumab Shows Benefits in Two Phase III Gouty Arthritis Studies")
![Genentech is taking over full responsibility for ocrelizumab against multiple sclerosis.[James Steidl-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesOct2010Oct22_2010_1247716_TugOfWar_GenentechBiogenIdecReviseMScollab9864522415-265x198.jpg "Biogen Idec and Genentech Tweak Anti-CD20 Alliance to Prevent Future Squabbles")